February 23-26, 2024, Washington, DC, USA

American Academy of Allergy Asthma & Immunology (AAAAI)

February 24-27, 2023, San Antonio, TX

American Academy of Allergy Asthma & Immunology (AAAAI)

American Academy of Allergy Asthma & Immunology (AAAAI)

thumb icon

Efficacy of remibrutinib in patients with chronic spontaneous urticaria with or without prior exposure to biologics in the Phase 3 REMIX-1 and REMIX-2 studies

G. Mosnaim, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, M. Maurer, M. Metz, S. Saini,
G. Sussman, S. Haemmerle, K. Lheritier, El-D. Martzloff, N. Seko, P. Wang, S. Gogate
thumb icon

Remibrutinib monotherapy reduced rescue medication in chronic spontaneous urticaria patients: Findings from a Phase 2b extension study

L. Clore, W. Carr, J. Tillinghast, V. Jain, J. Reed, P. Staubach, K. Lheritier, P. Walsh,
I. Nikolaev, S. Haemmerle, A.M. Giménez-Arnau
thumb icon

Remibrutinib treatment has no impact on mean blood cell counts in patients with chronic spontaneous urticaria: Results from Phase 2, 52-week extension study

A. Greiner, V. Jain, A.M Giménez-Arnau, J. Tillinghast, K. Lheritier, P. Walsh, S. Haemmerle, A. Zharkov, R. Snyder
thumb icon

Remibrutinib treatment did not impact mean total serum immunoglobulin levels or infection rates in patients with chronic spontaneous urticaria: Phase 2b study results

W. Carr, A.M. Giménez-Arnau, K. Lheritier, S. Haemmerle, A. Zharkov, S. Dahale,
K. Hayama, R. Snyder
thumb icon

Frequency of angioedema in chronic spontaneous urticaria patients: Report from the Urticaria Voices study

J.A. Bernstein, T.A. Winders, M-M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Kuruvilla,
K. Weller
thumb icon

Time to relapse during treatment-free follow-up without remibrutinib in patients with chronic spontaneous urticaria: Subgroup analysis by baseline immunoglobulin-E levels and chronic urticaria index status from a Phase 2b extension study

A. Greiner, V. Jain, A.M. Giménez-Arnau, J. Tillinghast, K. Lheritier, S. Haemmerle, P. Walsh, I. Nikolaev, R. Snyder
thumb icon

Burden of angioedema among patients with chronic spontaneous urticaria in the United States

D. Patil, M-M. Balp, J. Rodrigues, R.K. Kohli, K. Krupsky, B.L. Balkaran, S. Gupta,
B.J. Williams, W. Soong
thumb icon

Long-term treatment with remibrutinib shows favorable safety profile and sustained efficacy in patients with chronic spontaneous urticaria: Final results from the 52-week Phase 2b extension study

W. Carr, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier, P. Walsh, M. Wells, A. Zharkov, S. Hugot, A.M. Giménez-Arnau
thumb icon

Remibrutinib improves chronic spontaneous urticaria in patients irrespective of previous anti-Ige treatment: Results from a Phase 2b study

A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev, A.M. Giménez-Arnau, M. Maurer
thumb icon

Efficacy and safety of ligelizumab in chronic spontaneous urticaria: Results from the Phase-3 pivotal trials

L.F. Ensina, J.A. Bernstein, G. Sussman, M. Maurer, A.M. Giménez-Arnau, S. Saini, V. Varanasi, A. Barve, E. Hua, M. Patekar, T. Severin

2022

thumb icon

Ligelizumab achieves freedom from signs and symptoms of chronic spontaneous urticaria regardless of the CU index (basophil histamine release assay) status at baseline

K. Sitz, J. A. Bernstein, W. Soong, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin
thumb icon

Ligelizumab improves dermatology quality of life in patients with chronic spontaneous urticaria regardless of angioedema status at baseline

W. Soong, J. A. Bernstein, K. Sitz, M. Maurer, A. M. Giménez-Arnau, C. E. Ortmann, T. Severin
thumb icon

Ligelizumab for adolescent patients with CSU: First results from a dedicated Phase 2b study

M. Ben-Shoshan, B. E. Sekerel, P. Staubach, M. Alvaro-Lozano, M. Maurer, A. Drollmann,
A. Bienczak, M. Porter, T. Liu, A. Burciu, T. Severin
thumb icon

Remibrutinib treatment improves quality of life in patients with chronic spontaneous urticaria

M. Maurer, A. M. Giménez-Arnau, V. Jain, J. Tillinghast, A. Tolcachier, S. Nigen,
K. Hayama, K. Lheritier, P. Walsh, S. Haemmerle

2021

thumb icon

Ligelizumab is more effective in patients with chronic spontaneous urticaria previously treated with omalizumab

K. Sitz, G. Sussman, M. Metz, M. Hide, M. Maurer, N. Barbier, E. Hua, R. Janocha, T. Severin

2020

thumb icon

Long-term treatment with ligelizumab achieves prolonged symptom control during the post-treatment follow-up

W. Soong, JA. Bernstein, G. Sussman, B. Lanier, K. Sitz, M. Maurer, A. Giménez-Arnau, E. Hua, A. Barve, T. Severin, R. Janocha
AAAAI 2020 was postponed to 2021 and the presentations submitted to the congress were published. The virtual meeting conducted in 2020 included recordings of selected sessions.

2018 and 2019

No publication submitted this year

© Copyright 2024 Novartis Pharma AG